Stem Cells for Diabetes

Type 1 diabetes results from autoimmune destruction of the insulin-producing beta cells inside pancreatic islets, and unlike most conditions covered in this section, stem cell science offers a mechanistically direct fix: growing replacement islet cells from stem cells and transplanting them back into the patient. This has produced some of the clearest efficacy data of any stem cell application, alongside two very different technical approaches to solving immune rejection.

Vertex Pharmaceuticals' zimislecel, known during development as VX-880, uses fully differentiated pancreatic islet cells derived from stem cells, delivered by hepatic portal vein infusion alongside standard immunosuppression to prevent rejection. Pivotal trial results published in the New England Journal of Medicine in June 2025 followed 14 participants with type 1 diabetes for at least 12 months [1]. All 14 had undetectable C-peptide, a marker of native insulin production, at baseline, and all showed evidence of islet cell engraftment and function after infusion [1]. Among the 12 participants in the trial's later dosing cohorts, 10, or 83%, achieved insulin independence at day 365, with zero severe hypoglycemic events, hemoglobin A1c below 7%, and glucose readings in target range more than 70% of the time [1][2]. Two participants died during the trial, one from cryptococcal meningitis and one from progressive dementia with agitation; investigators assessed both deaths as unrelated to the treatment itself [1]. Mean daily insulin dose fell by 92% and time-in-range reached 93.3% among responders, according to Vertex's own detailed data presentation [2]. Vertex completed enrollment and dosing for its pivotal Phase 3 program in the first half of 2025 and expects regulatory submissions in 2026 [3].

Vertex ran a parallel companion program, VX-264, using the same stem-cell-derived islet cells but housed in an immune-protective device intended to eliminate the need for immunosuppression entirely. That device-based approach failed to meet its efficacy endpoint, according to the company's own program update, illustrating that the encapsulation strategy for avoiding immunosuppression remains a harder technical problem than the cell biology itself [3].

ViaCyte pursued a related device-based approach earlier, using PEC-01 cells derived from the CyT49 human embryonic stem cell line inside a perforated subcutaneous device (VC-02, marketed as PEC-Direct) that allows blood vessels to grow in while still containing the transplanted cells. An interim report on a 10-patient open-label Phase 1/2 cohort, published in Nature Biotechnology in 2023, showed evidence of meal-stimulated insulin secretion and improved glucose control in engrafted patients [4]. ViaCyte's technology and patient base were subsequently absorbed into Vertex's islet cell program.

A separate and more experimental approach uses induced pluripotent stem cells made from a patient's own reprogrammed cells rather than donor-derived stem cell lines. Researchers at Shanghai Changzheng Hospital reported in Cell in September 2024 what they describe as the first case of a person with type 1 diabetes achieving sustained insulin independence after autologous transplantation of islet cells derived from chemically induced pluripotent stem cells [5]. Because this used the patient's own reprogrammed cells, it in principle avoids the need for long-term immunosuppression that Vertex's allogeneic approach requires, though this remains a single case report, not a controlled trial, and longer-term safety data comes only from prior nonhuman primate studies that showed no tumor formation [5]. A related endoderm stem cell-derived islet program from the same broader Chinese research ecosystem, registered as NCT05294822, has since entered broader clinical evaluation [6].

Diabetes stands out from other indications in this encyclopedia because the efficacy signal is unusually large and unambiguous: an 83% insulin-independence rate at one year in a chronic, currently incurable autoimmune disease is a result that would be considered a major clinical breakthrough in almost any therapeutic area. The tradeoff is that Vertex's approach still requires immunosuppressive drugs, which carry their own long-term infection and cancer risks, and the therapy remains unapproved as of mid-2026, with regulatory submissions expected only in 2026. This combination of strong efficacy signal, ongoing immunosuppression tradeoff, and pending regulatory review places stem cell therapy for type 1 diabetes in tier 2 of our evidence framework, with a plausible path to tier 1 once larger trials and regulatory decisions land.

A new review published in *Metabolism* on 18 August 2026 mapped 107 registered interventional MSC trials from 124 screened records [7]. Jhuang, Lee, and Wang report that early programs used autologous bone-marrow and adipose-derived MSCs, while newer registrations increasingly use allogeneic umbilical-cord MSCs and cell-free derivatives [7]. The most consistent clinical signal is in ischemic and wound-healing complications, particularly diabetic foot ulcers. Metabolic outcomes remain variable. The review describes early safety as generally favorable but explicitly calls for larger randomized trials with harmonized endpoints before efficacy is considered established [7]. This updates the pipeline picture, not the evidence tier: registered studies are not equivalent to completed, controlled outcome trials, and the review does not show that MSC therapy reverses biological aging or cures diabetes.